Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical’s President and CEO Christophe Weber has reported his initial ownership position on a Form 3. The filing lists direct holdings of 935,300 Ordinary Shares and 253,433 American Depositary Shares, plus various equity-based awards tied to future vesting dates.
The position includes 96,000 restricted stock units (RSUs) linked to Ordinary Shares, vesting on June 1, 2026 (46,100 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares. It also includes 204,008 RSUs linked to American Depositary Shares, vesting on July 1, 2026 (95,744 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares).
Weber also holds Tax Obligation Awards that are economically equivalent to Ordinary Shares, with underlying amounts of 46,367, 32,966 and 17,296 Ordinary Shares, expiring on June 1, 2026, June 1, 2027 and June 1, 2028. Upon vesting, these Tax Obligation Awards convert into cash payments primarily to cover tax obligations based on the then-current Ordinary Share price.
Takeda Pharmaceutical director John Maraganore reports his equity interests in the company. He shows direct holdings of 7,600 American Depositary Shares and 9,700 Ordinary Shares, along with Tax Obligation Awards that are economically equivalent to 1,152, 1,192 and 1,180 Ordinary Shares.
The filing also describes restricted stock unit awards that each convert into one Ordinary Share and then into an equivalent number of American Depositary Shares. These RSUs vest in tranches of 3,100, 3,400 and 3,200 shares on June 1, 2026, June 1, 2027 and June 1, 2028, respectively.
Takeda Pharmaceutical executive Giles Richard Platford, President of PDT, filed an initial ownership report showing beneficial ownership of 225,239 American Depositary Shares. This total includes 94,620 restricted stock units, each representing a contingent right to receive one American Depositary Share.
The restricted stock units vest over three dates: 44,638 shares on July 1, 2026, 32,396 shares on July 1, 2027, and 17,586 shares on July 1, 2028. These awards reflect equity-based compensation that will convert into shares only as they vest over time.
TAKEDA PHARMACEUTICAL CO LTD director Ian T. Clark filed an initial ownership report showing his existing equity interests in the company. The filing lists direct holdings of 9,696 American Depositary Shares and 9,700 Ordinary Shares, along with several equity-based awards.
These include "Tax Obligation Awards" economically equivalent to Ordinary Shares that will be settled in cash primarily to cover tax obligations, and a cash-settled retirement RSU award tied to the value of 2,356 Ordinary Shares. Additional RSU grants are scheduled to vest in tranches on June 1, 2026, June 1, 2027 and June 1, 2028, with each unit linked to one Ordinary Share and converting into American Depositary Shares upon vesting.
Takeda Pharmaceutical Co. Ltd. director Steven Gillis filed an initial Form 3 reporting his beneficial holdings. He directly holds 9,700 Ordinary Shares and 15,857 American Depositary Shares.
He also reports several equity-based awards. Tax Obligation Awards are each economically equivalent to one Ordinary Share and, upon vesting, will be settled in cash primarily to cover tax obligations at the then-current market price of the Ordinary Shares. A separate Cash Settled Retirement Award consists of restricted stock units that pay cash equal to the value of one Ordinary Share at vesting, which occurs upon his retirement from the board. Another RSU award will convert into Ordinary Shares, then into an equivalent number of American Depositary Shares as it vests on June 1, 2026 (3,100 Ordinary Shares), June 1, 2027 (3,400 Ordinary Shares) and June 1, 2028 (3,200 Ordinary Shares).
TAKEDA PHARMACEUTICAL CO LTD director and President of R&D Andrew Stewart Plump filed an initial Form 3 reporting his holdings in American Depositary Shares. He reports 594,102 ADS held directly and 281,307 ADS held indirectly through a trust. A footnote states that these figures include 251,962 restricted stock units that convert into ADS as they vest on July 1, 2026, July 1, 2027, and July 1, 2028.
Takeda Pharmaceutical Co Ltd executive Lauren Rusckowski Duprey reports her initial beneficial ownership of 168,513 American Depositary Shares. This includes 86,772 restricted stock units, each representing a right to receive one share. The RSUs vest in stages: 40,668 shares on July 1, 2026, 30,488 on July 1, 2027, and 15,616 on July 1, 2028, reflecting a multi-year equity compensation package aligned with her role as Chief HR Officer.
TAKEDA PHARMACEUTICAL CO LTD director Masami Iijima has filed an initial ownership report. The filing shows direct ownership of 12,801 Ordinary Shares and Tax Obligation Awards linked to 2,152, 2,392 and 2,280 underlying Ordinary Shares. It also notes 6,400 restricted stock units that vest in tranches of 2,100, 2,200 and 2,100 shares on June 1, 2026, 2027 and 2028, respectively. Each Tax Obligation Award is economically equivalent to one Ordinary Share and is settled in cash at vest primarily to cover tax obligations.
TAKEDA PHARMACEUTICAL CO LTD director Koji Hatsukawa filed an initial ownership report showing equity and award holdings in the company. He directly holds 25,834 Ordinary Shares.
He also holds several Tax Obligation Awards, each economically equivalent to one Ordinary Share and intended to be settled in cash at vesting primarily to cover tax obligations. These awards reference 2,152, 2,392, 2,280 and 2,318 underlying Ordinary Shares, with scheduled vesting or expiration dates between June 1, 2026 and June 1, 2028 or upon conclusion of board service.
In addition, the holdings include an award of 8,600 restricted stock units, each representing a contingent right to receive one Ordinary Share. These RSUs vest in tranches of 2,100, 2,200, and 2,100 shares on June 1, 2026, 2027 and 2028, with a final 2,200-share tranche vesting upon retirement from board service.
Takeda Pharmaceutical Company reported that the U.S. FDA has accepted the New Drug Application and granted Priority Review for rusfertide, an investigational first-in-class hepcidin mimetic peptide for adults with polycythemia vera. The agency set a Prescription Drug User Fee Act target action date in the third quarter of this calendar year.
The NDA is primarily supported by the Phase 3 VERIFY study, where rusfertide plus standard of care more than doubled clinical response rates versus standard care alone, as well as four-year efficacy and safety data from Phase 2 REVIVE/THRIVE studies. Rusfertide met its primary and all four key secondary endpoints and was generally well-tolerated, with injection site reactions, anemia and fatigue as the most common adverse events.
Rusfertide has also received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. Takeda states that the impact of the NDA acceptance on its financial results for the fiscal year ending March 31, 2026 is immaterial.